Get the Stockscreener App
7.01
3.31%
-0.24
After Hours:
7.01
Avita Medical Inc stock is traded at $7.01, with a volume of 497.81K.
It is down -3.31% in the last 24 hours and down -18.68% over the past month.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$7.25
Open:
$7.26
24h Volume:
497.81K
Relative Volume:
2.13
Market Cap:
$243.46M
Revenue:
$50.14M
Net Income/Loss:
$-35.38M
P/E Ratio:
-5.0071
EPS:
-1.4
Net Cash Flow:
$-39.46M
1W Performance:
-23.89%
1M Performance:
-18.68%
6M Performance:
-45.53%
1Y Performance:
-16.05%
1-Day Range:
$6.77
$7.4299
1-Week Range:
$6.60
$9.845
52-Week Range:
$6.60
$14.16
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCEL
Avita Medical Inc
|
7.01 | 243.46M | 50.14M | -35.38M | -39.46M | -1.40 |
|
ABT
Abbott Laboratories
|
129.05 | 231.50B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.95 | 154.04B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.53 | 144.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.11 | 105.58B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.50 | 43.95B | 5.54B | 4.18B | 623.10M | 7.00 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-24-24 | Initiated | D. Boral Capital | Buy |
| Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-21 | Initiated | Piper Sandler | Overweight |
| Aug-27-20 | Initiated | BofA Securities | Buy |
| Apr-21-20 | Initiated | Oppenheimer | Outperform |
| Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
AVITA downgraded by Piper Sandler over sales outlook - MSN
AVITA Medical's Acute Wound Care Showcase 2025 Streams Live Today - The Manila Times
AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today - Stock Titan
AVITA Medical: Near Perfect Execution Needed To Navigate Through Balance Sheet Challenges - Seeking Alpha
Why AVITA, Botanix, Brainchip, and NAB shares are falling today - The Motley Fool Australia
Analysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest Report - Yahoo Finance
Contrasting GBS (NYSE:GBS) and AVITA Medical (NASDAQ:RCEL) - Defense World
Wells Fargo & Company MN Boosts Stock Position in AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
AVITA Medical, Inc. (NASDAQ:RCEL) Q1 2025 Earnings Call Transcript - Insider Monkey
Cantor maintains Avita Medical stock Overweight, $19 target post-Q1 By Investing.com - Investing.com Canada
AVITA Medical outlines $3.5B US market opportunity with expanded product portfolio and 2025 revenue guidance - MSN
Avita Medical (RCEL) Target Price Adjusted by TD Cowen | RCEL St - GuruFocus
Avita Medical Shares Decline on 1Q Revenue Miss - MarketWatch
Barclays PLC Purchases 3,526 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Avita’s Road to Profitability Is in Sight - Morningstar
AVITA Medical (RCEL) Sees Revenue Surge with Product Launches - GuruFocus
AVITA Medical Inc (AVHHL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
AVITA Medical Inc (AVHHL) Q1 2025 Earnings Call Highlights: Stro - GuruFocus
Avita Medical Earnings: Fair Value Estimate Cut on Unlikely Vitiligo Reimbursement Support - Morningstar
AVITA Medical Inc (AVHHL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Shifts - GuruFocus
AVITA Medical Reports Strong Q1 2025 Growth - TipRanks
Avita Medical's Loss Narrows in Q1 as Revenue Grows; Shares Down 20% - marketscreener.com
AVITA Medical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
AVITA Medical Q1 2025 slides reveal growth strategy as stock tumbles on earnings miss - Investing.com Canada
AVITA Medical (RCEL) Reports Significant Revenue Growth with New Product Launches | RCEL Stock News - GuruFocus
AVITA Medical Reports First Quarter 2025 Financial Results - The Manila Times
AVITA Medical (RCEL) Projected to Post Earnings on Thursday - MarketBeat
(RCEL) Long Term Investment Analysis - news.stocktradersdaily.com
AVITA Medical, Inc. (NASDAQ:RCEL) Shares Bought by JPMorgan Chase & Co. - Defense World
Russell Investments Group Ltd. Acquires 2,324 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
Geode Capital Management LLC Raises Stock Position in AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025 - Stock Titan
Avita Uses Its Tech To Treat Wounds - Los Angeles Business Journal
AVITA Medical to Announce First Quarter 2025 Financial Results - The Manila Times
AVITA Medical to Announce First Quarter 2025 Financial Results | RCEL Stock News - GuruFocus
Leading Wound Care Company AVITA Medical Announces Q1 2025 Earnings Call Details - Stock Titan
The new medical device company to watch - Morningstar
Vanguard Group Inc. Has $18.22 Million Stock Holdings in AVITA Medical, Inc. (NASDAQ:RCEL) - Defense World
AVITA Medical, Inc. Announces Chief Executive Officer Changes - marketscreener.com
D. Boral Capital Reiterates Buy Rating for AVITA Medical (NASDAQ:RCEL) - Defense World
AVITA Medical, Inc.'s (NASDAQ:RCEL) Profit Outlook - simplywall.st
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 | RCEL Stock News - GuruFocus
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 - The Manila Times
AVITA Medical (NASDAQ:RCEL) Receives "Buy" Rating from D. Boral Capital - MarketBeat
AVITA Medical (NASDAQ:RCEL) Earns “Buy” Rating from D. Boral Capital - Defense World
6 Analysts Assess AVITA Medical: What You Need To Know - Benzinga
AVITA Medical Announces US Commercial Launch Of Cohealyx - marketscreener.com
Avita Medical's Cohealyx Wound Treatment Makes Commercial Launch in US; Shares Down 4% - MarketScreener
AVITA Medical launches Cohealyx in the U.S. market By Investing.com - Investing.com South Africa
AVITA Medical Launches Wound Care Product Cohealyx in US - MarketScreener
AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity - The Manila Times
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):